A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults

Summary

The purpose of this study is to compare multiple formulations of PF-07220060 in terms of their uptake into the blood stream. The study will assess the effects of food and Rabeprazole on the uptake of PF-07220060. Rabeprazole belongs to a type of medications called proton pump inhibitors. In reality, some patients may take both PF-07220060 and rabeprazole together.

This study is seeking participants that are:

\- Healthy male or female aged 18 to 65 years

Participants in this study will receive PF-07220060 once or twice by mouth. The participants may receive different tablets for PF-07220060. Some participants will take a meal before receiving PF-07220060. In addition, some participants will take rabeprazole by mouth for 7 days before taking PF-07220060.

The study will compare experiences of people receiving different formulations of PF-07220060. Experiences of people taking food and rabeprazole with PF-07220060 will be compared to those on PF-07220060 alone. This will help understand how much PF-07220060 is taken up into the blood. It will also help understand how meal and Rabeprazole medicine changes the uptake of PF-07220060 into the blood.

Participants will take part in the study for a maximum of 74 days. During this time, they will have to stay onsite for 5 to 13 days. There will be up to 2 onsite study visits.

Conditions

• Healthy Participants

Interventions

DRUG

Single dose of PF-07220060 as first Tablet Formulation

A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions.

DRUG

Single dose of PF-07220060 as second Tablet Formulation

A single dose of PF-0720060 as the second Tablet Formulation administered under fasting conditions

DRUG

Single dose of PF-07220060 as first Tablet Formulation

A single dose of PF-07220060 as the first Tablet Formulation administered under fasting conditions at a second dose level

DRUG

Single dose of PF-07220060 as second Tablet Formulation

A single dose of PF-07220060 as the second Tablet Formulation administered under fasting conditions at a second dose level

DRUG

Single dose of PF-07220060 as a Tablet Formulation

A single dose of PF-07220060 as a tablet formulation administered under fed conditions

DRUG

Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration

A 2-treatment fixed sequence of single dose of PF-07220060 tablets under fasting conditions followed by a single dose of PF-07220060 tablets under Proton Pump Inhibitor (PPI) administration under fasting condition (following a 7 day oral rabeprazole tablets daily administration).

DRUG

Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administration

A 2-treatment fixed sequence of a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal followed by a single dose of PF-07220060 tablet given with moderate-fat, standard-calorie meal and under PPI administration (following a 7 day oral rabeprazole tablets daily administration)

DRUG

Single dose of PF-07220060 as third tablet formulation

A 2-period randomized 2-sequence cross over of a single dose of PF-07220060 as first and third tablet formulation under fasting conditions with a 6-day washout in between them

Sponsors & Collaborators

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-07-11

Primary Completion

2024-06-23

Completion

2024-07-19

FDA Drug

Yes

Countries

• United States

Study Locations